Bavarian Nordic Announces Major Shareholder Notification from ATP

Copenhagen, Denmark, April 2, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today, as set out in Section 38 in the Danish Capital Markets Act and section 55, cf. 56 of the Danish Companies Act, received the following major shareholder notification from ATP: 

“ATP has increased its ownership in Bavarian Nordic. Subsequently, ATP holds a total of 11.12% of the share capital and voting rights in Bavarian Nordic A/S.” 

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit

Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43 

Graham Morrell, Paddock Circle Advisors (US)
Tel: +1 781 686 9600 

Company Announcement no. 21 / 2020

Published on April 02, 2020, 12:13 CET